Arcadia Biosciences Completes First Commercial Production Of SONOVA™ 400 High GLA Safflower Oil

Main Category: Nutrition / Diet
Also Included In: Pharma Industry / Biotech Industry
Article Date: 15 Mar 2010 - 5:00 PDT

email to a friend   printer friendly   opinions  

Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, announced today that it has successfully completed the first commercial production of SONOVA™ 400 High GLA Safflower Oil. Seed produced by the first High GLA Safflower crop, grown during 2009, was processed to produce commercial quantities of SONOVA™ 400 oil, which is now available for distribution as a key ingredient in dietary supplements. SONOVA™ 400 is being launched at SupplyExpo 2010 being held March 12-14 in Anaheim, Calif.

SONOVA™ 400, developed through a combination of plant breeding and modern biotechnology, delivers 400 milligrams (mg) of gamma-linolenic acid (GLA) per gram, making it the most concentrated, convenient and cost-effective source of GLA available.

GLA is an important nutritional omega-6 fatty acid with documented health benefits that are similar and complementary to the benefits of omega-3 fatty acids. Numerous published studies show the benefits of GLA supplementation, including anti-inflammatory effects, and improved skin health and appearance. A recent study by Schirmer and Phinney found that GLA supplementation also plays a key role in maintaining weight loss.

Currently, evening primrose and borage oils are the two main sources of dietary GLA, containing 10 percent and 20 percent GLA, respectively. The availability of SONOVA™ 400, with over 40 percent GLA - twice the GLA concentration of borage oil - provides consumers with the option of taking fewer capsules or smaller capsules to obtain their desired level of GLA supplementation.

In December, 2009, Arcadia announced that it had completed the U.S. Food and Drug Administration (FDA) regulatory process for SONOVA™ 400, allowing it to be marketed and sold as an ingredient in dietary supplements.

"Completion of our first oil processing run represents one more successful step along the pathway to commercializing this important new product," said Eric Rey, president and CEO of Arcadia. "Consumers and manufacturers have been asking for a more concentrated and cost-effective source of GLA. Following successful completion of the FDA process, completion of this first production run and achieving our intended oil quality targets allows us to commercialize SONOVA™ 400, making the benefits of GLA more broadly available to consumers on a cost-effective basis."

SONOVA™ 400 is marketed and sold by Bioriginal Food and Science Corporation, a global provider of essential fatty acid (EFA) solutions.

Source
Arcadia Biosciences, Inc.

• Additional
• References
• Citations